25.37
Tumorimmunotherapie
Immunotherapie is een behandeling die het immuunsysteem stimuleert of manipuleert om ziektes te bestrijden, waaronder kanker. Door bijvoorbeeld een im…
Cancer immunotherapy aids the body's immune system to identify and eliminate cancer cells, using vaccines, oncolytic viruses, activated patient T cells, and immune checkpoint regulators.
Treatment vaccines are designed using cells from the patient, like dendritic cells, which are loaded with tumor antigens to stimulate an immune response.
Alternatively, oncolytic virus therapy uses native or engineered viruses to infect cancer cells selectively.
For example, T-VEC, a genetically modified herpes virus, can selectively lyse cancer cells and release tumor antigens for additional cytotoxic T cell responses.
In contrast, adoptive cell therapy modifies a patient's T cells, which can be edited to express chimeric antigen receptors or CARs.
Once reinfused, these CAR T cells can directly bind and destroy specific cancer cells.
Some tumor cells exploit binding partners of immune checkpoint proteins, such as CTLA-4 on T cells, down-regulating immune response.
Antibodies, like ipilimumab, are immune checkpoint inhibitors that block CTLA-4 from interacting with the tumor cells, enhancing T cell proliferation against tumor antigens.
View the full transcript and gain access to JoVE Core videos
Q1: How do cancer treatment vaccines work to fight tumors?
Cancer treatment vaccines are designed using dendritic cells loaded with tumor antigens from the patient's own cancer cells. These antigen-presenting cells stimulate an immune response, training the body to recognize and attack cancer cells. This approach leverages the patient's adaptive immune system to target malignant cells specifically.
Q2: What is CAR T cell therapy and how does it eliminate cancer?
Adoptive cell therapy modifies a patient's T cells to express chimeric antigen receptors, or CARs, which enable direct recognition of cancer cells. Once reinfused into the patient, CAR T cells bind to specific tumor antigens and destroy cancer cells. This personalized approach harnesses the patient's own immune cells as targeted cancer fighters.
Q3: How do oncolytic viruses like T-VEC treat cancer?
Oncolytic virus therapy uses genetically modified viruses, such as T-VEC, a herpes virus variant, to selectively infect and lyse cancer cells. When tumor cells rupture, they release tumor antigens that trigger additional cytotoxic T cell responses. This dual mechanism combines direct cell destruction with immune system activation.
Q4: What role do immune checkpoint inhibitors play in cancer treatment?
Tumor cells exploit immune checkpoint proteins like CTLA-4 on T cells to suppress immune responses. Checkpoint inhibitor antibodies, such as ipilimumab, block these interactions, preventing tumor cells from evading immunity. By removing this inhibition, these antibodies enhance T cell proliferation and activation against tumor antigens.
Q5: Why do some cancer cells escape the immune system?
Cancer cells evade immunity through rapid mutation and division, allowing them to avoid recognition by immune surveillance mechanisms. The immune response to cancer involves three phases: elimination, equilibrium, and escape. Understanding these phases helps researchers develop strategies to enhance early immune responses and prevent tumor escape.
Q6: How is immunotherapy administered to cancer patients?
Immunotherapy can be delivered through multiple routes including intravenous, oral, topical, and intravesical administration. Treatment frequency and duration depend on cancer type, stage, the specific immunotherapy used, and the patient's response. Regular medical check-ups and tests monitor treatment effectiveness and guide adjustments.
Q7: What are the main types of cancer immunotherapy approaches?
Cancer immunotherapy includes several strategies: immune checkpoint inhibitors, T-cell transfer therapy, monoclonal antibodies, treatment vaccines, and immune system modulators. Each approach targets different mechanisms to enhance the body's ability to recognize and eliminate cancer cells. These therapies work by boosting or manipulating immune responses against malignant tumors.